Volume : 12, Issue : 08, August- 2025
Title:
A REVIEW ON INFLAMMASOMES AND CARDIOVASCULAR DISEASE: THE NLRP3 AXIS AS A THERAPEUTIC FRONTIER
Authors :
Rohith Yadav, Shubamalya LG
Abstract :
Cardiovascular diseases (CVDs) are the leading worldwide cause of morbidity and mortality, inflammation being one of the main factors in their pathology. Inflammasomes, NLRP3 in particular, were identified as central mediators of sterile inflammation processes. NLRP3 inflammasomes are cytosolic multiprotein complexes that control caspase-1 activation and subsequent maturation of pro-inflammatory cytokines IL-1β and IL-18. With growing evidence, NLRP3 inflammasome has been implicated in CVDs like atherosclerosis, myocardial infarction, heart failure, and hypertension. Their activation causes endothelial dysfunction, vascular inflammation, destabilization of plaques, and adverse cardiac remodeling. Targeting the NLRP3 axis therapeutically has been promising in both preclinical and clinical studies, thus presenting NLRP3 as a potential new target in cardiovascular therapy. This study reviews the mechanistic insights of NLRP3 inflammasome activation, its involvement in cardiovascular diseases, current therapeutic strategies, and hurdles in clinical translation. Exploration of this inflammasome axis brings new avenues for precision medicine and targeted interventions for cardiovascular health.
Keywords: NLRP3, inflammasome, cardiovascular disease, inflammation, IL-1β, atherosclerosis, myocardial infarction, heart failure.
Cite This Article:
Please cite this article in press Rohith Yadav et al., A Review On Inflammasomes And Cardiovascular Disease: The Nlrp3 Axis As A Therapeutic Frontier., Indo Am. J. P. Sci, 2025; 12(08).
Number of Downloads : 10
References:
1. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, McGhie DV, Mwangi J, Pervan B, Narula J, Pineiro D, Pinto FJ. The Heart of the World. Glob Heart. 2024 Jan 25;19(1):11.
2. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018 May;34(5):575-584
3. Yao, J., Sterling, K., Wang, Z. et al. The role of inflammasomes in human diseases and their potential as therapeutic targets. Sig Transduct Target Ther 9, 10 (2024).
4. Chen, Y., Ye, X., Escames, G. et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett 28, 51 (2023).
5. Dai Y, Zhou J, Shi C. Inflammasome: structure, biological functions, and therapeutic targets. MedComm (2020). 2023 Oct 9;4(5):e391
6. Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Ther. 2025 Jul 11;10(1):216.
7. Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem. 2012 Dec 7;287(50):41732-43.
8. Stein R, Kapplusch F, Heymann MC, Russ S, Staroske W, Hedrich CM, Rösen-Wolff A, Hofmann SR. Enzymatically Inactive Procaspase 1 stabilizes the ASC Pyroptosome and Supports Pyroptosome Spreading during Cell Division. J Biol Chem. 2016 Aug 26;291(35):18419-29
9. Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 2020 Jun 9;6:36.
10. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019 Jul 6;20(13):3328.
11. Pyrillou K, Burzynski LC, Clarke MCH. Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease. Front Immunol. 2020 Dec 18;11:613170.
12. Khare S, Luc N, Dorfleutner A, Stehlik C. Inflammasomes and their activation. Crit Rev Immunol. 2010;30(5):463-87.
13. Tong Y, Wang Z, Cai L, Lin L, Liu J, Cheng J. NLRP3 Inflammasome and Its Central Role in the Cardiovascular Diseases. Oxid Med Cell Longev. 2020 Apr 14;2020:4293206
14. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019 Aug;19(8):477-489
15. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014 Jun;1319(1):82-95
16. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013 Jun;13(6):397-411
17. Raneros AB, Bernet CR, Flórez AB, Suarez-Alvarez B. An Epigenetic Insight into NLRP3 Inflammasome Activation in Inflammation-Related Processes. Biomedicines. 2021 Nov 4;9(11):1614
18. Zheng Y, Xu L, Dong N, Li F. NLRP3 inflammasome: The rising star in cardiovascular diseases. Front Cardiovasc Med. 2022 Sep 20;9:927061
19. Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021 Sep;18(9):2114-2127
20. Liang JJ, Fraser IDC, Bryant CE. Lipid regulation of NLRP3 inflammasome activity through organelle stress. Trends Immunol. 2021 Sep;42(9):807-823
21. Ji N, Qi Z, Wang Y, Yang X, Yan Z, Li M, Ge Q, Zhang J. Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease. J Inflamm Res. 2021 Jun 22;14:2647-2666.
22. Karasawa T, Takahashi M. Role of NLRP3 Inflammasomes in Atherosclerosis. J Atheroscler Thromb. 2017 May 1;24(5):443-45144
23. Shen S, Wang Z, Sun H, Ma L. Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling. Med Sci Monit. 2022 Jan 19;28:e934255
24. Butts B, Gary RA, Dunbar SB, Butler J. The Importance of NLRP3 Inflammasome in Heart Failure. J Card Fail. 2015 Jul;21(7):586-93
25. González-Moro A, Valencia I, Shamoon L, Sánchez-Ferrer CF, Peiró C, de la Cuesta F. NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically. Antioxidants (Basel). 2022 Jan 29;11(2):269.
26. Xing Y, Yan L, Li X, Xu Z, Wu X, Gao H, Chen Y, Ma X, Liu J, Zhang J. The relationship between atrial fibrillation and NLRP3 inflammasome: a gut microbiota perspective. Front Immunol. 2023 Nov 21;14:1273524.
27. Chiarini A, Gui L, Viviani C, Armato U, Dal Prà I. NLRP3 Inflammasome’s Activation in Acute and Chronic Brain Diseases-An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes. Biomedicines. 2023 Mar 23;11(4):999.
28. Ding K, Song C, Hu H, Yin K, Huang H, Tang H. The Role of NLRP3 Inflammasome in Diabetic Cardiomyopathy and Its Therapeutic Implications. Oxid Med Cell Longev. 2022 Sep 6;2022:3790721.
29. Das B, Sarkar C, Rawat VS, Kalita D, Deka S, Agnihotri A. Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models. Molecules. 2021 Aug 18;26(16):4996.
30. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020 Apr 24;126(9):1260-1280.
31. Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, Van Tassell BW, Abbate A. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022 Aug;236:108053
32. Zhao S, Chen F, Yin Q, Wang D, Han W, Zhang Y. Reactive Oxygen Species Interact With NLRP3 Inflammasomes and Are Involved in the Inflammation of Sepsis: From Mechanism to Treatment of Progression. Front Physiol. 2020 Nov 25;11:571810.
33. Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012 Jan;226(2):365-79.
34. Singh DD. NLRP3 inflammasome: structure, mechanism, drug-induced organ toxicity, therapeutic strategies, and future perspectives. RSC Med Chem. 2025 May 13.
35. Mo B, Ding Y, Ji Q. NLRP3 inflammasome in cardiovascular diseases: an update. Front Immunol. 2025 Feb 26;16:1550226.